531 related articles for article (PubMed ID: 30895619)
1. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
4. EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells.
Poursheikhani A; Yousefi H; Tavakoli-Bazzaz J; Seyed H G
Iran Biomed J; 2020 Nov; 24(6):370-8. PubMed ID: 32660222
[TBL] [Abstract][Full Text] [Related]
5. RIF1 promotes human epithelial ovarian cancer growth and progression via activating human telomerase reverse transcriptase expression.
Liu YB; Mei Y; Long J; Zhang Y; Hu DL; Zhou HH
J Exp Clin Cancer Res; 2018 Aug; 37(1):182. PubMed ID: 30075819
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
7. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
8. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
9. Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells.
Kang H; Jeong JY; Song JY; Kim TH; Kim G; Huh JH; Kwon AY; Jung SG; An HJ
Mol Carcinog; 2016 Jul; 55(7):1196-209. PubMed ID: 26207830
[TBL] [Abstract][Full Text] [Related]
10. HYOU1 promotes cell growth and metastasis via activating PI3K/AKT signaling in epithelial ovarian cancer and predicts poor prognosis.
Li X; Zhang NX; Ye HY; Song PP; Chang W; Chen L; Wang Z; Zhang L; Wang NN
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(10):4126-4135. PubMed ID: 31173282
[TBL] [Abstract][Full Text] [Related]
11. BRMS1L suppresses ovarian cancer metastasis via inhibition of the β-catenin-wnt pathway.
Cao P; Zhao S; Sun Z; Jiang N; Shang Y; Wang Y; Gu J; Li S
Exp Cell Res; 2018 Oct; 371(1):214-221. PubMed ID: 30118697
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
Long X; Song K; Hu H; Tian Q; Wang W; Dong Q; Yin X; Di W
J Exp Clin Cancer Res; 2019 Aug; 38(1):345. PubMed ID: 31391118
[TBL] [Abstract][Full Text] [Related]
13. NKX2-8 deletion-induced reprogramming of fatty acid metabolism confers chemoresistance in epithelial ovarian cancer.
Zhu J; Wu G; Song L; Cao L; Tan Z; Tang M; Li Z; Shi D; Zhang S; Li J
EBioMedicine; 2019 May; 43():238-252. PubMed ID: 31047858
[TBL] [Abstract][Full Text] [Related]
14. miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells.
Wang Y; Yan C; Qi J; Liu C; Yu J; Wang H
Mol Cell Biochem; 2022 Jan; 477(1):307-317. PubMed ID: 34716858
[TBL] [Abstract][Full Text] [Related]
15. CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer.
Nie S; Wan Y; Wang H; Liu J; Yang J; Sun R; Meng H; Ma X; Jiang Y; Cheng W
J Ovarian Res; 2021 Sep; 14(1):115. PubMed ID: 34474677
[TBL] [Abstract][Full Text] [Related]
16. Gli affects the stemness and prognosis of epithelial ovarian cancer via homeobox protein NANOG.
Zhao H; Li N; Pang Y; Zhao J; Wu X
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33313950
[TBL] [Abstract][Full Text] [Related]
17. Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer.
Fletcher NM; Belotte J; Saed MG; Memaj I; Diamond MP; Morris RT; Saed GM
Free Radic Biol Med; 2017 Jan; 102():122-132. PubMed ID: 27890641
[TBL] [Abstract][Full Text] [Related]
18. ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer.
Nie S; Zhang L; Liu J; Wan Y; Jiang Y; Yang J; Sun R; Ma X; Sun G; Meng H; Xu M; Cheng W
J Exp Clin Cancer Res; 2021 Sep; 40(1):284. PubMed ID: 34496932
[TBL] [Abstract][Full Text] [Related]
19. Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells.
Luo Y; Gui R
J Gynecol Oncol; 2020 Sep; 31(5):e75. PubMed ID: 32808501
[TBL] [Abstract][Full Text] [Related]
20. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.
Zhang P; Zhang P; Shi B; Zhou M; Jiang H; Zhang H; Pan X; Gao H; Sun H; Li Z
Cell Death Dis; 2014 Jan; 5(1):e991. PubMed ID: 24407244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]